Suthergrey House Medical Centre
37A St Johns Road, Watford, Hertfordshire, WD17 1LS
Sorry, we're currently closed. Please call NHS 111

Telephone: 01923 224 424
Out of Hours: 111
Covid Vaccination Clinics
WE ARE NOW CALLING ALL PATIENTS OVER 18Y EARLY FOR THEIR COVID BOOSTER SHOTS – 3 MONTHS AFTER SECOND DOSE (OR THIRD PRIMARY DOSE)- 4 WEEKS AFTER A POSTIVE COVID TEST
WE RUN WEEKLY SMALL COVID VACCINE CLINICS AT SUTHERGREY HOUSE – PLEASE CONTACT RECEPTION TO BOOK YOUR APPOINTMENT ASAP
WE HAVE PFIZER AND MODERNA VACCINES
JCVI advice on COVID-19 booster vaccines for those aged 18 to 39 and a second dose for ages 12 to 15 – published 29/11/21
CURRENT NHS GUIDANCE FOR 12 TO 17 YEAR OLDS- updated 2/12/21:
Risk of COVID-19 infection in children
The children and young people at greater risk include those living with serious conditions such as:
– cancers (such as leukaemia or lymphoma)
– diabetes
– serious heart problems
– chest complaint or breathing difficulties, including poorly controlled asthma
– kidney, liver or a gut disease
– lowered immunity due to disease or treatment (steroid medication, chemotherapy or radiotherapy)
– an organ transplant
– a neurodisability or neuromuscular condition
– a severe or profound learning disability
– Down’s syndrome
– a problem with your spleen, for example sickle cell disease, or you have had your spleen removed
– epilepsy
– serious genetic problems
– other serious medical conditions as advised by your doctor or specialist
For most children and young people COVID-19 is usually a milder illness that rarely leads to complications. For a very few the symptoms may last for longer than the usual 2 to 3 weeks. The vaccination will help to protect you against COVID-19.
Currently the vaccine licensed for children and young people is the Pfizer vaccine. This is what you will be offered.
Latest Green Book Guidance on vaccination following COVID infection in children:
In younger people, protection from natural infection is likely to be high for a period of months, and vaccination in those recently infected may increase the chance of side effects. Therefore, vaccination should ideally be deferred till at least twelve weeks from onset (or sample date) in children and young people under 18 years who are not in clinical risk groups.
This includes children and young people who developed Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) in association with COVID-19 infection and then become eligible for vaccination. Current advice in PIMS-TS cases suggests that an interval of 12 weeks should be observed, although earlier administration can be considered in those at risk of infection and/or who are fully recovered.